The Hepatitis Policy Project has released a new brief that makes recommendations for how the Ryan White HIV/AIDS Program can leverage its role at the forefront of the nation’s HIV response to also play a significant role in eliminating hepatitis C (HCV) in the U.S. by expanding screening and testing within its clinical network.
The report is authored by Sonia Canzater and Jeffrey S. Crowley of the O’Neill Institute, and is informed by a convening held in April 2018 of experts from varied aspects of HIV and HCV law, policy, advocacy, and treatment.
In this report, the authors identify four priority actions:
Comprehensive efforts to overcome financial, clinical, and other barriers to treatment
Better metrics for tracking progress toward elimination
Increased emphasis on re-screening of key populations
Strengthened planning and commitment to HCV elimination in states, communities, and clinics
These recommendations work in tandem with actions the U.S. Department of Health and Human Services and the Health Resources and Services Administration are taking to respond to HCV among people living with HIV.
The Hepatitis Policy Project is supported by a grant from Gilead Sciences, Inc. Gilead Sciences, Inc. has had no input into the development of or content of this policy brief.
The views reflected in this expert column are those of the individual authors and do not necessarily represent those of the O’Neill Institute for National and Global Health Law or Georgetown University. This blog is solely informational in nature, and not intended as a substitute for competent legal advice from a licensed and retained attorney in your state or country.